Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.
David Samuel DiCapua Siegel
Consultant or Advisory Role - Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Research Funding - Celgene; Millennium
Expert Testimony - Onyx
Thomas Martin
Consultant or Advisory Role - Onyx
Honoraria - Celgene
Seema Singhal
Consultant or Advisory Role - Celgene; Millennium; Takeda
Research Funding - Onyx
Michael Wang
Research Funding - Onyx
Ravi Vij
Consultant or Advisory Role - Celgene; Onyx
Honoraria - Celgene; Onyx
Research Funding - Celgene; Onyx
Andrzej J. Jakubowiak
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Onyx
Honoraria - Bristol-Myers Squibb; Celgene; Millennium; Onyx
Sundar Jagannath
Consultant or Advisory Role - Celgene; Merck; Millennium; Takeda
Honoraria - Celgene
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Vishal Kukreti
Honoraria - Celgene
Nizar J. Bahlis
No relevant relationships to disclose
Melissa Alsina
Consultant or Advisory Role - Millennium; Novartis
Research Funding - Allergan; Millennium
Asher Alban Akmal Chanan-Khan
No relevant relationships to disclose
Francis Buadi
No relevant relationships to disclose
Frederic J. Reu
No relevant relationships to disclose
George Somlo
No relevant relationships to disclose
Lori A. Kunkel
Consultant or Advisory Role - Onyx
Stock Ownership - Onyx
Kanya Rajangam
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
Yu-Lin Chang
Employment or Leadership Position - Onyx
Robert Z. Orlowski
Honoraria - Onyx
A. Keith Stewart
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Novartis; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Novartis; Onyx